Orange Book product · Brand (NDA)
RAPIVAB
PERAMIVIR
At a glance
Dec 19, 2014
Approved
Brand (NDA)
Application
Not listed
TE code
5
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 19, 2014
11 yr 8 mo ago
Today
Patent 10391075 expires
Listed method-of-use patent (U-2622) expiration.
Feb 12, 2027
in 8 mo
Patent 10391075 expires
Listed method-of-use patent (U-3069) expiration.
Feb 12, 2027
in 8 mo
Patent 8778997 expires
Listed method-of-use patent (U-2622) expiration.
May 07, 2027
in 11 mo
Patent 8778997 expires
Listed method-of-use patent (U-1627) expiration.
May 07, 2027
in 11 mo
Patent 8778997 expires
Listed method-of-use patent (U-3069) expiration.
May 07, 2027
in 11 mo
Pharmaceutical detail
Active ingredient
PERAMIVIR
Strength
200MG/20ML (10MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 206426
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (5)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10391075 | Feb 12, 2027 | in 8 mo | U-2622 |
| 10391075 | Feb 12, 2027 | in 8 mo | U-3069 |
| 8778997 | May 07, 2027 | in 11 mo | U-2622 |
| 8778997 | May 07, 2027 | in 11 mo | U-1627 |
| 8778997 | May 07, 2027 | in 11 mo | U-3069 |
